Literature DB >> 21666087

Oral ferrous sulfate does not increase preoperative hemoglobin in patients scheduled for hip or knee arthroplasty.

Kim Lachance1, Michel Savoie, Maryse Bernard, Stéphanie Rochon, Josée Fafard, Robert Robitaille, Pascal-André Vendittoli, Sylvie Lévesque, Simon de Denus.   

Abstract

BACKGROUND: Low hemoglobin (Hb) concentrations before lower limb joint replacement are associated with the need for blood transfusions and increased mortality. To optimize preoperative Hb, blood conservation protocols often recommend oral iron supplements, even in nonanemic patients.
OBJECTIVE: To investigate the impact of ferrous sulfate on the change in Hb prior to hip or knee arthroplasty and evaluate the effect of oral iron on hematocrit, mean corpuscular volume (MCV), ferritin, and transferrin saturation, as well as its tolerability and treatment adherence.
METHODS: We conducted a prospective, observational cohort study of adults with Hb concentrations between 10 and 15 g/dL who received iron supplementation prior to hip or knee arthroplasty. Systemic inflammatory diseases, vitamin B(12) or folate deficiency, and current use of iron supplements, intravenous iron, or erythropoietin were exclusion criteria. All participants were prescribed ferrous sulfate 300 mg 3 times daily for a minimum of 3 weeks. Complete blood cell counts and iron studies were performed before therapy and surgery.
RESULTS: Eighty-seven patients with a mean (SD) Hb of 13.47 (0.84) g/dL were included in the study. Preoperative Hb decreased after treatment with iron (-0.14 [0.53] g/dL, p = 0.015). Hematocrit also declined (-0.6% [1.8%], p = 0.002), whereas ferritin increased (25.8 [38.6] ng/mL, p < 0.001). No significant change was seen in MCV and transferrin saturation. The most common adverse effects were constipation (33.3%), heartburn (13.8%), and abdominal pain (12.6%). The adherence rate was 67.1%.
CONCLUSIONS: Oral ferrous sulfate supplementation is not an effective method to increase preoperative Hb in patients scheduled for hip or knee arthroplasty, and its use is associated with adverse effects.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21666087     DOI: 10.1345/aph.1P757

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  9 in total

Review 1.  Pre-operative anaemia: prevalence, consequences and approaches to management.

Authors:  Manuel Muñoz; Susana Gómez-Ramírez; Arturo Campos; Joaquín Ruiz; Giancarlo M Liumbruno
Journal:  Blood Transfus       Date:  2015-06-16       Impact factor: 3.443

2.  EFFICACY OF EXTENDED ORAL TRANEXAMIC ACID ON BLOOD LOSS IN PRIMARY TOTAL KNEE ARTHROPLASTY.

Authors:  Varah Yuenyongviwat; Kantapon Dissaneewate; Khanin Iamthanaporn; Pakjai Tuntarattanapong; Theerawit Hongnaparak
Journal:  Acta Ortop Bras       Date:  2022-07-06       Impact factor: 0.683

3.  Can tranexamic acid change preoperative anemia management during total joint arthroplasty?

Authors:  Duy L Phan; Joseph B Rinehart; Ran Schwarzkopf
Journal:  World J Orthop       Date:  2015-08-18

Review 4.  Current misconceptions in diagnosis and management of iron deficiency.

Authors:  Manuel Muñoz; Susana Gómez-Ramírez; Martin Besser; José Pavía; Fernando Gomollón; Giancarlo M Liumbruno; Sunil Bhandari; Mercé Cladellas; Aryeh Shander; Michael Auerbach
Journal:  Blood Transfus       Date:  2017-09       Impact factor: 3.443

5.  Clinical evaluation of iron treatment efficiency among non-anemic but iron-deficient female blood donors: a randomized controlled trial.

Authors:  Sophie Waldvogel; Baptiste Pedrazzini; Paul Vaucher; Raphael Bize; Jacques Cornuz; Jean-Daniel Tissot; Bernard Favrat
Journal:  BMC Med       Date:  2012-01-24       Impact factor: 8.775

6.  Iron therapy for preoperative anaemia.

Authors:  Oliver Ng; Barrie D Keeler; Amitabh Mishra; J A Simpson; Keith Neal; Hafid Omar Al-Hassi; Matthew J Brookes; Austin G Acheson
Journal:  Cochrane Database Syst Rev       Date:  2019-12-07

7.  [Perioperative blood management for total hip/knee arthroplasty].

Authors:  Mingcheng Yuan; Zichuan Ding; Tingxian Ling; Zongke Zhou
Journal:  Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi       Date:  2020-12-15

8.  Intravenous iron isomaltoside 1000 (Monofer®) reduces postoperative anaemia in preoperatively non-anaemic patients undergoing elective or subacute coronary artery bypass graft, valve replacement or a combination thereof: a randomized double-blind placebo-controlled clinical trial (the PROTECT trial).

Authors:  P I Johansson; A S Rasmussen; L L Thomsen
Journal:  Vox Sang       Date:  2015-04-20       Impact factor: 2.144

9.  The Important Role for Intravenous Iron in Perioperative Patient Blood Management in Major Abdominal Surgery: A Randomized Controlled Trial.

Authors:  Bernd Froessler; Peter Palm; Ingo Weber; Nicolette A Hodyl; Rajvinder Singh; Elizabeth M Murphy
Journal:  Ann Surg       Date:  2016-07       Impact factor: 12.969

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.